13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02200718 (ClinicalTrials.gov) | December 31, 2020 | 17/7/2014 | A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant | Immune Response BioPharma, Inc. | NULL | Not yet recruiting | 5 Years | 17 Years | All | 12 | Phase 1 | United States |
2 | NCT02149706 (ClinicalTrials.gov) | March 9, 2020 | 24/5/2014 | A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination | Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant | Immune Response BioPharma, Inc. | cro | Not yet recruiting | 18 Years | 70 Years | All | 150 | Phase 2 | United States |